Is C677T Polymorphism in Methylenetetrahydrofolate Reductase Gene a Risk Factor for Diabetic Nephropathy or Diabetes Mellitus in a Chinese Population?

Archives of Medical Research

Volumn 43, Issue 1, 2012, Pages 42-50

  Cui, Wen Peng ^a   Du, Bing ^a   Jia, Ye ^a   Zhou, Wen Hua ^a   Liu, Sheng Mao ^a   Cui, Ying Chun ^a   Ma, Fu Zhe ^a   Luo, Ping ^a   Miao, Li Ning ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

C677T Polymorphism; Diabetes mellitus; Diabetic nephropathy; Meta analysis; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ARTICLE; C677T GENE; CHINA; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOMINANT GENE; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; RECESSIVE GENE; RISK; SENSITIVITY ANALYSIS;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK FACTORS;

EID: 84859239810     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.12.003     Document Type: Article

References (62)

1. Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(suppl 1):S12-S54. American Diabetes Association.
2. Gross J.L., de Azevedo M.J., Silveiro S.P., et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
3. Guilbert J.J. The World Health Report 2006: working together for health. Educ Health 2006, 19:385-387.
4. Wu A.Y., Kong N.C., de Leon F.A., et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005, 48:17-26.
5. Parving H.H., Lewis J.B., Ravid M., et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006, 69:2057-2063.
6. Chi Z.S., Lee E.T., Lu M., et al. Vascular disease prevalence in diabetic patients in China: standardised comparison with the 14 centres in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001, 44(suppl 2):S82-S86.
7. Mooyaart A.L., Valk E.J., van Es L.A., et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia 2011, 54:544-553.
8. Nemr R., Salman R.A., Jawad L.H., et al. Differential contribution of MTHFR C677T variant to the risk of diabetic nephropathy in Lebanese and Bahraini Arabs. Clin Chem Lab Med 2010, 48:1091-1094.
9. Ukinc K., Ersoz H.O., Karahan C., et al. Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine 2009, 36:255-261.
10. Zintzaras E., Stefanidis I. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet 2005, 50:84-91.
11. Movva S., Alluri R.V., Venkatasubramanian S., et al. Association of methylene tetrahydrofolate reductase C677T genotype with type 2 diabetes mellitus patients with and without renal complications. Genet Test Mol Biomarkers 2011, 15:257-261.
12. Eroglu Z., Erdogan M., Tetik A., et al. The relationship of the methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Metab Res Rev 2007, 26:621-624.
13. Mtiraoui N., Ezzidi I., Chaieb M., et al. MTHFR C677T and A1298C gene polymorphisms a hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2007, 75:99-106.
14. Böger C.A., Stubanus M., Haak T., et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nehprol Dial Transplant 2007, 22:154-162.
15. Fujita H., Narita T., Meguro H., et al. No association between MTHFR gene polymorphism and diabetic nephropathy in Japanese type diabetic patients with proliferative diabetic retinopathy. J Diabetes Complic 1999, 13:284-287.
16. Lau J., Ioannidis J.P., Schmid C.H. Summing up evidence: one answer is not always enough. Lancet 1998, 351:570-573.
17. Huang Y., Han S., Li Y., et al. Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Hum Genet 2007, 52:73-85.
18. Spiridonova M.G., Stepanov V.A., Maksimova N.R., et al. Population study of frequency of methylenetetrahydrofolate reductase C677T gene polymorphism in Yakutia. Genetika 2004, 40:704-708.
19. Lau J., Ioannidis J.P., Schmid C.H. Qauntitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
20. Zintzaras E., Ioannidis J.P. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 2005, 21:3672-3673.
21. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
22. Zhang Y.D., Shi L., Yu M., et al. Correlation between single nucleotide polymorphisms in methylenetetrahydrofolate reductase gene and type 2 diabetes mellitus in Chinese Han nationality. J Mod Lab Med 2010, 25:14-16.
23. Lin R., Wang C.N., Liu X.M. Matched case-control study on the association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene and diabetic nephropathy in type 2 diabetic patients. Modern Prevent Med 2009, 36:3801-3804.
24. Chen P., Pan Y.H., Sun D.L., et al. The association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene and type 2 diabetes mellitus. J Qiqihar Med Coll 2008, 29:672-673.
25. Wen J., Chen Z.Q., Li X.M., et al. Correlation of MTHFR gene polymorphism and plasma homocysteine with microalbuminuria in type 2 diabetes. Shanghai Med J 2008, 31:47-51.
26. Yue H., Liu J., Kang W.J., et al. Relationship between plasma level of homocysteine and urine microalbumin in incipient type 2 diabetic nephropathy. Chin J Gen Pract 2006, l5:725-729.
27. Cao H., Huang D.F., Mao L., et al. Association of homocysteine, methyleneterahydrofolate reductase gene polymorphism with nephropathy in type 2 diabetes mellitus. ACTA Universitatis Medicinalis Nanjing (Natural Science) 2005, 25:249-251.
28. Chen A.R., Ning Y.Y., Zhu X.Z., et al. Study on the relationship between gene polymorphisms of N5,10-methylenetetrahydrofolate reductase and nephropathy in type 2 diabetes mellitus in Gansu Han Chinese of China. Clin J Prev Contr Chron Non-Commun Dis 2004, 12:195-197.
29. Sun J.Z., Xu Y.C., Zhu Y.L., et al. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabet Res Clin Pract 2004, 64:185-190.
30. Xu J.S., Zhang J., Shan B.E., et al. Relationship between methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy in type 2 diabetes mellitus in the Hans of Hebei Province. Clin Focus 2003, 18:787-789.
31. Sun J.Z., Xu Y.C., Zhu Y.L., et al. The association of methylenetetrahydrofolate reductase gene polymorphism with diabetic nephropathy in type 2 diabetes mellitus in Chinese. Chin J Intern Med 2001, 40:529-532.
32. Wang L.Q., Wang J.Y., Xue Y.M., et al. Relationship between methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy. Chin J Med Genet 2001, 18:226-228.
33. Yang G.Q., Lu J.M., Pan C.Y. Study on the relationship between N5,10-methylenetetrahydrofolate reductase gene polymorphism and the susceptibility to microangiopathy in type 2 diabetes mellitus. Chin J Endocrinol Metab 2001, 17:224-227.
34. Hozyasz K.K., Mostowska A., Szaflarska-Poplawska A., et al. Polymorphic variants of genes involved in homocysteine metabolism in celiac disease. Mol Biol Rep 2011, 29:13-20.
35. Galati G., Gentilucci U.V., Mazzarelli C., et al. Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations. Am J Med Sci 2011, 342:79-82.
36. Mataradzija A., Resić H., Rasić S., et al. Risk factors for development of cardiovascular complications in patients with chronic renal disease and diabetic nephropathy. Bosn J Basic Med Sci 2010, 10(suppl 1):S44-S50.
37. Cho E.H., Kim E.H., Kim W.G., et al. Homocysteine as a risk factor for development of microalbuminuria in type 2 diabetes. Korean Diabetes J 2010, 34:200-206.
38. Yi F., dos Santos E.A., Xia M., et al. Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats. Am J Nephrol 2007, 27:262-268.
39. Kumagai H., Katoh S., Hirosawa K., et al. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002, 62:1219-1228.
40. Yi F., Zhang A.Y., Li N., et al. Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int 2006, 70:88-96.
41. Ingram A.J., Krepinsky J.C., James L., et al. Activation of mesangial cell MAPK in response to homocysteine. Kidney Int 2004, 66:733-745.
42. Hwang S.Y., Woo C.W., Au-Yeung K.K., et al. Homocysteine stimulates monocyte chemoattractant protein-1 expression in the kidney via nuclear factor-kappa B activation. Am J Physiol Renal Physiol 2008, 294:236-244.
43. Sung S.H., Ziyadeh F.N., Wang A., et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006, 17:3093-3104.
44. Roybal C.N., Yang S., Sun C.W., et al. Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem 2004, 279:14844-14852.
45. Maeda M., Yamamoto I., Fujio Y., et al. Homocysteine induces vascular endothelial growth factor expression in differentiated THP-1 macrophages. Biochim Biophys Acta 2003, 1623:41-46.
46. de Vasconcelos H.C., de Araújo M.F., Damasceno M.M., et al. Risk factors for type 2 diabetes mellitus among adolescents. Rev Esc Enferm USP 2010, 44:881-887.
47. Vijaya Lakshmi S.V., Naushad S.M., Rupasree Y., et al. Interactions of 5'-UTR thymidylate synthase polymorphism with 677C→T methylene tetrahydrofolate reductase and 66A→G methyltetrahydrofolate homocysteine methyl-transferase reductase polymorphisms determine susceptibility to coronary artery disease. J Atheroscler Thromb 2011, 27:56-64.
48. Isordia-Salas I., Trejo-Aguilar A., Valadés-Mejía M.G., et al. C677T polymorphism of the 5,10 MTHFR gene in young Mexican subjects with ST-elevation myocardial infarction. Arch Med Res 2010, 41:246-250.
49. Ilhan N., Kucuksu M., Kaman D., et al. The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res 2008, 39:125-130.
50. Somarajan B.I., Kalita J., Mittal B., et al. Evaluation of MTHFR C677T polymorphism in ischemic and hemorrhagic stroke patients. A case-control study in a Northern Indian population. J Neurol Sci 2011, 304:67-70.
51. Saetre P., Vares M., Werge T., et al. Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and age of onset in schizophrenia: a combined analysis of independent samples. Am J Med Genet B Neuropsychiatr Genet 2011, 156:215-224.
52. Banerjee I., Gupta V., Ganesh S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: a meta-analysis. J Hum Genet 2007, 52:205-219.
53. De Marco P., Calevo M.G., Moroni A., et al. Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population. J Hum Genet 2002, 47:319-324.
54. Levine A.J., Lee W., Figueiredo J.C., et al. Variation in folate pathway genes and distal colorectal adenoma risk: a sigmoidoscopy-based case-control study. Cancer Causes Control 2011, 22:541-552.
55. Zintzaras E., Giannouli S., Rodopoulou P., et al. The role of MTHFR gene in multiple myeloma. J Hum Genet 2008, 53:499-507.
56. Mao R., Fan Y., Jin Y., et al. Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis. J Hum Genet 2008, 53:340-348.
57. Moczulski D., Fojcik H., Zukowska-Szczechowska E., et al. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003, 18:1535-1540.
58. Shpichinetsky V., Raz I., Friedlander Y., et al. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type IIdiabetic patients. J Nutr 2000, 130:2493-2497.
59. Jafari Y., Rahimi Z., Vaisi-Raygani A., et al. Interaction of eNOS polymorphism with MTHFR variants increases the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients. Mol Cell Biochem 2011, 353:23-24.
60. Rahimi M., Hasanvand A., Rahimi Z., et al. Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. Clin Biochem 2010, 43:1333-1339.
61. Maeda M., Yamamoto I., Fukuda M., et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complic 2008, 22:119-125.
62. Yoshioka K., Yoshida T., Umekawa T., et al. Methylenetetrahydrofolate reductase gene polymorphism is not related to diabetic nephropathy in Japanese type 2 diabetic patients. Diabet Med 2004, 21:1051-1052.